How good are we at preventing HIV? How do efficacy and effectiveness differ? We journey from oral pre-exposure prophylaxis (PrEP) to long-acting injectables, and then to the PURPOSE trials, which look at the use of long-acting lenacapavir as PrEP — a potential game-changer in the field of HIV.

Listen to this latest episode of Beyond Journal Club, a collaboration between CoreIM and NEJM Group, where we put research into context, telling the story of how we arrived at the current standard of care, appreciating the clinical question of the trial at hand, and interpreting what the findings may mean for these patients.

🔹 Sponsor:  NEJM Fellowship Program, click here to learn more and/or apply!

🔹 Transcript and Show Notes

Timestamps:

(02:25) | HIV PrEP Daily Truvada and Descovy

(07:48) | On-Demand Prep

(13:25) | Purpose Trials

(20:56) | Discussion of Effectiveness to Efficacy

Tags:  CoreIM, Internal Medicine, Primary Care, Medical Education, IMCore, Physician Assistant, Nurse Practitioner, Medical Student, HIV Prevention, Infectious Disease

Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840

Our Sponsors:
* Check out Thrive Market for 30% off your first order, plus a FREE $60 gift! : https://thrivemarket.com/coreim
* Sponsor: FIGS! Use code FIGSRX for 15% off: https://wearfigs.com


Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy